Company intelligence / Profile preview

Shanxi Wanglong Pharmaceutical Group

Ownership: Private
Employees: ~500
Development stage: Other

Overview

Shanxi Wanglong Pharmaceutical Group is a comprehensive pharmaceutical manufacturer with GMP-certified facilities producing APIs such as dextran variants and L-malic acid. The company also manufactures finished dosage forms including tablets, capsules, injections, and traditional Chinese medicines. Its portfolio includes both generic drugs and exclusive formulations. Products are commercialized in China and exported internationally.

Therapeutic areas: Metabolic DisordersInfectious Diseases
Modalities: Small moleculeBiologic
Industry: Biotech

Drug pipeline

4 assets

Nankang Tablets

Unknown

3 more assets in the full pipeline.

Partnerships

Not specified; likely partners with global distributors given export focus.

Beyond the preview

Go deeper on Shanxi Wanglong Pharmaceutical Group.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shanxi Wanglong Pharmaceutical Group.